United States KRAS Tests Market was valued at USD 0.55 Billion in 2022 and is projected to reach USD 1.2 Billion by 2030, growing at a CAGR of 10.4% from 2024 to 2030.
The US KRAS tests market has been growing steadily, driven by an increasing demand for personalized treatment and diagnostic tools for cancer patients. KRAS (Kirsten rat sarcoma viral oncogene homolog) mutations are significant biomarkers for several types of cancer, including lung, colon, and pancreatic cancer. The KRAS test is used to detect these mutations and assist in identifying the most appropriate treatment options for patients. As a result, healthcare providers, pharmaceutical companies, and research institutions are relying more heavily on KRAS testing for targeted therapies, fueling the market’s expansion.
One of the primary requirements for industries in the US KRAS tests market is the need for precision and reliability in diagnostic tools. As more targeted therapies become available, the importance of accurate KRAS testing grows. This drives the need for advanced and innovative testing technologies, including next-generation sequencing (NGS) and polymerase chain reaction (PCR) methods, which offer high sensitivity and specificity for detecting KRAS mutations. Additionally, the integration of these tests into clinical decision-making has made them indispensable in oncology practice.
The increasing prevalence of cancer in the United States, especially lung and colorectal cancers, has further amplified the demand for KRAS tests. In fact, research suggests that over 30% of non-small cell lung cancer (NSCLC) cases have KRAS mutations, underlining the critical role of KRAS testing in identifying suitable treatments. Pharmaceutical companies are also investing heavily in the development of KRAS inhibitors, contributing to a growing focus on genetic testing in oncology.
Another vital aspect of the KRAS tests market is the growing collaboration between diagnostic companies and healthcare providers. Companies are working to ensure that their tests are not only clinically accurate but also user-friendly and cost-effective. This collaboration is helping to reduce the barriers to access, ensuring that more patients benefit from KRAS testing, ultimately improving patient outcomes.
In conclusion, the US KRAS tests market is poised for significant growth due to the increasing prevalence of cancer, the demand for targeted therapies, and the continuous advancements in testing technology. As the market expands, it will be essential for industries to meet the increasing demand for precision diagnostics, ensuring that patients receive the most effective treatments available.
Get an In-Depth Research Analysis of the US KRAS Tests Market Size And Forecast [2025-2032]
Qiagen NV
F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific Inc
Takara Bio Inc
Panagene Inc
Amoy Diagnostics Co Ltd
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the US KRAS Tests Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the US KRAS Tests Market
PCR-based Tests
Next-Generation Sequencing (NGS)
Hybridization-based Tests
Reagents and Kits
Instruments
Software
Services
Hospitals
Diagnostic Laboratories
Research Institutions
Pharmaceutical Companies
Oncolog
Infectious Diseases
Genetic disorders
Personalized Medicine
Sequencing Technology
Microarray Technology
FISH (Fluorescence In Situ Hybridization)
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ KRAS Tests Market Research Analysis
1. Introduction of the US KRAS Tests Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. US KRAS Tests Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. US KRAS Tests Market, By Type
6. US KRAS Tests Market, By Application
7. US KRAS Tests Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. US KRAS Tests Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading US Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/